Table 1 Patient baseline clinical characteristics according to body mass index
| Â | Low BMI group | Moderate BMI group | High BMI group | P value |
|---|---|---|---|---|
(n = 1034) | (n = 369) | (n = 263) | ||
Age (years) | 66.3 ± 10.6 | 63.2 ± 10.5 | 59.1 ± 12.0 | < 0.01* |
Male | 77.2% | 84.8% | 74.5% | < 0.01* |
Body mass index (kg/m2) | 22.3 ± 1.8 | 26.0 ± 0.7 | 30.2 ± 2.7 | < 0.01* |
Hypertension | 69.8% | 78.0% | 83.3% | < 0.01* |
Diabetes mellitus | 36.9% | 40.9% | 47.1% | < 0.01* |
Dyslipidemia | 67.6% | 73.2% | 83.3% | < 0.01* |
Smoking history | 43.8% | 51.8% | 46.0% | 0.03* |
Family history of ischemic heart disease | 19.1% | 19.8% | 18.3% | 0.89 |
Total cholesterol (mg/dl) | 189.4 ± 34.6 | 191.7 ± 36.9 | 190.1 ± 38.9 | 0.66 |
Triglycerides (mg/dl) | 138.3 ± 83.8 | 164.2 ± 117.4 | 160.9 ± 87.5 | < 0.01* |
Low-density lipoprotein cholesterol (mg/dl) | 109.3 ± 29.8 | 113.3 ± 29.9 | 112.0 ± 33.2 | 0.13 |
High-density lipoprotein cholesterol (mg/dl) | 53.2 ± 16.9 | 47.5 ± 15.4 | 48.4 ± 12.8 | < 0.01* |
Hemoglobin A1c (%) | 6.2 ± 1.0 | 6.3 ± 1.1 | 6.4 ± 1.0 | 0.02* |
Estimated glomerular filtration rate (ml/min/1.73 m2) | 68.7 ± 17.2 | 67.2 ± 17.9 | 68.8 ± 18.0 | 0.44 |
EPA (μg/dl) | 72.9 ± 42.6 | 76.2 ± 45.4 | 70.3 ± 43.1 | 0.23 |
DHA (μg/dl) | 141.2 ± 50.0 | 147.2 ± 54.3 | 143.8 ± 59.8 | 0.16 |
DGLA (μg/dl) | 31.9 ± 11.8 | 34.0 ± 12.4 | 36.9 ± 13.1 | < 0.01* |
AA (μg/dl) | 154.6 ± 41.3 | 159.4 ± 71.8 | 163.2 ± 40.2 | 0.02* |
EPA/AA | 0.49 ± 0.30 | 0.50 ± 0.30 | 0.44 ± 0.29 | 0.04* |
DHA/AA | 0.95 ± 0.41 | 0.96 ± 0.31 | 0.90 ± 0.36 | 0.11 |
Statins | 51.5% | 55.8% | 61.2% | 0.01* |
Antiplatelet agents | 65.0% | 68.0% | 58.9% | 0.059 |
Angiotensin II receptor blocker | 34.2% | 45.8% | 44.1% | < 0.01* |
Calcium channel blockers | 42.6% | 54.5% | 47.9% | < 0.01* |
Beta blockers | 38.4% | 40.4% | 41.1% | 0.64 |
Hypoglycemic agents | 20.5% | 23.8% | 20.9% | 0.39 |
ACS events | 9.2% | 7.3% | 10.3% | 0.39 |